LEDGF Binds H3R17me2a Promoting De Novo Nucleotide Biosynthesis in SETD2 Mutant Clear Cell Renal Cell Carcinoma
Advanced Science · 2025
DOI: 10.1002/advs.202416809 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Science, 2025. Verfasst von Yuwei Zhang und 11 weiteren Autor:innen. Beteiligte Einrichtung: Medical School of Nantong University, 9 Qiangyuan Road, Nantong, 226019, China. Hauptthemen laut MEDLINE: Carcinoma, Renal Cell, Histone-Lysine N-Methyltransferase, Kidney Neoplasms, Histones. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: CMC Excellent-talent Program, Postgraduate Research & Practice Innovation Program of Jiangsu Province, National Natural Science Foundation of China.
Abstract (Originalsprache)
Previous studies have identified that lens epithelium‐derived growth factor (LEDGF) interacts with SETD2‐dependent histone H3 trimethylated at lysine 36 (H3K36me3) to mediate transcriptional elongation. However, the original LEDGF recognition H3K36me3 epigenetic regulatory axis no longer exists in SETD2 mutant clear cell renal cell carcinoma (ccRCC) patients, and a new transcription system needs to be discovered. In this study, the authors demonstrated the novel interaction between LEDGF and H3R17me2a. In detail, Asn38 and Asp57 of LEDGF Proline‐Tryptophan‐Tryptophan‐Proline (PWWP) domain are the key binding sites validated by peptide pull‐down assays. Subsequently, a series of in vitro and in vivo experiments showed that PPAT , PAICS , GART , ADSL , and ADSS2 are key target genes. Collectively, LEDGF binds H3R17me2a to regulate purine nucleotide metabolism in SETD2 mutant ccRCC cells, promoting tumor proliferation, and may be an effective therapeutic target.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Medical School of Nantong University, 9 Qiangyuan Road, Nantong, 226019, China.
- Department of Urology, Jiangnan University Medical Center, 68 Zhongshan Road, Wuxi, 214002, China.
- Wuxi School of Medicine, Jiangnan University, 1800 Lihu Avenue, Wuxi, 214122, China.
- School of Clinical Medicine, The First Affiliated Hospital, Chengdu Medical College, 783 Xindu Avenue, Chengdu, 610500, China.
- The Affiliated Taizhou People's Hospital, Taizhou School of Clinical Medicine, Nanjing Medical University, 101 Longmian Avenue, Nanjing, 211166, China.
- Department of Urology, The Second Affiliated Hospital of Nanjing Medical University, 121 Jiangjiayuan, Nanjing, 210003, China.
ORCID-Profile: Ninghan Feng
Förderung
- CMC Excellent-talent Program
- Postgraduate Research & Practice Innovation Program of Jiangsu Province
- National Natural Science Foundation of China
Zitieren
APA
Zhang, Y., Zhou, Y., Zhang, Y., Lv, J., Shen, Y., Zhang, D., Liu, B., Zhao, W., Ju, J., Zhu, Q., Wang, K., & Feng, N. (2025). LEDGF Binds H3R17me2a Promoting De Novo Nucleotide Biosynthesis in SETD2 Mutant Clear Cell Renal Cell Carcinoma. Advanced Science. https://doi.org/10.1002/advs.202416809
Vancouver
Zhang Y, Zhou Y, Zhang Y, Lv J, Shen Y, Zhang D, et al. LEDGF Binds H3R17me2a Promoting De Novo Nucleotide Biosynthesis in SETD2 Mutant Clear Cell Renal Cell Carcinoma. Advanced Science. 2025. doi:10.1002/advs.202416809
BibTeX
@article{Zhang2025,
author = {Zhang, Yuwei and Zhou, Yuhua and Zhang, Yuezhou and Lv, Jing and Shen, Yang and Zhang, Dong and Liu, Bo and Zhao, Wei and Ju, Junyi and Zhu, Qingyi and Wang, Ke and Feng, Ninghan},
title = {LEDGF Binds H3R17me2a Promoting De Novo Nucleotide Biosynthesis in SETD2 Mutant Clear Cell Renal Cell Carcinoma},
journal = {Advanced Science},
year = {2025},
doi = {10.1002/advs.202416809}
}
EUVIMED